Neurophet
About Neurophet
Neurophet is a South Korea-based healthcare AI company specializing in advanced brain imaging analysis solutions and therapeutic medical devices for neurological disorders. For physicians, Neurophet offers a comprehensive suite of AI-driven software designed to support the entire cycle of brain disease management, from diagnosis and treatment guidance to monitoring. Key products include Neurophet AQUA, which performs brain atrophy analysis using T1-weighted MRI scans for neurodegenerative conditions like Alzheimer’s disease and Multiple Sclerosis, with recent FDA 510(k) clearance for MS analysis capabilities.
Their portfolio also features Neurophet AQUA AD Plus, an integrated solution for Alzheimer’s disease that quantitatively analyzes both MRI and PET images. This software automates the labeling, visualization, and volumetric quantification of brain structures and lesions, as well as standardized uptake value ratio (SUVR) analysis for PET tracers. It is particularly valuable for assessing patient eligibility for anti-amyloid antibody treatments, monitoring for amyloid-related imaging abnormalities (ARIA) such as cerebral microbleeds and edema, and evaluating treatment efficacy by measuring amyloid beta deposition. Additionally, Neurophet SCALE PET provides automated quantitative analysis of PET images for various brain imaging biomarkers, including amyloid and tau, and Neurophet tES/TMS LAB assists in planning electric and magnetic brain stimulation therapies.
What Physicians Need to Know
For physicians, Neurophet's tools offer enhanced diagnostic accuracy and speed through precise, automated quantitative analysis of neuroimaging, aiding in earlier and more confident diagnoses of neurodegenerative diseases. The ability to objectively monitor treatment efficacy and critical side effects, such as ARIA in anti-amyloid therapies, is invaluable for patient safety and management. The solutions support personalized treatment planning by providing detailed, patient-specific brain atrophy and lesion information. Furthermore, the automated analysis and intuitive reports streamline workflow, saving time and integrating seamlessly into existing hospital systems. The FDA clearances provide a strong assurance of the reliability and safety of these AI-powered medical devices, and their prognostic capabilities can help predict disease progression.
Neurophet's software solutions, such as Neurophet AQUA, are designed for integration into standard reading environments like PACS and can be deployed locally on dedicated hardware. The company is also actively pursuing collaborations, such as with ALZ-NET, to establish and facilitate imaging monitoring infrastructure for Alzheimer's disease therapies, indicating a focus on interoperability within clinical ecosystems.
What the Web Says
Neurophet, a South Korean company specializing in AI-powered brain analysis, has received positive attention for its FDA-cleared products like Neurophet AQUA AD Plus, which aids in Alzheimer's disease diagnosis. The company is recognized for its technological advancements in medical imaging and AI, particularly in neurodegenerative disease analysis. While product reviews highlight innovation and potential, there is limited public information regarding employer reviews on major platforms like Glassdoor or G2.
Overall: PositiveStrengths
- FDA clearance for multiple products (e.g., Neurophet AQUA AD Plus) indicates regulatory approval and reliability.
- Utilizes advanced AI technology for precise brain analysis, aiding in early diagnosis of neurodegenerative diseases.
- Strong focus on research and development, leading to innovative solutions in medical imaging.
- Potential to significantly improve diagnostic accuracy and patient outcomes for conditions like Alzheimer's.
- Positive media coverage regarding product milestones and technological achievements.
- Contribution to the advancement of digital healthcare and AI in medicine.
Limitations
- Limited publicly available employer reviews on platforms like Glassdoor, making it difficult to assess company culture or employee satisfaction.
- Scarcity of detailed product reviews from end-users (e.g., clinicians, hospitals) on platforms like G2 or Capterra.
- Specific pricing or accessibility information for their products is not readily available in public reviews.
- As a specialized medical technology company, its market reach and user base might be niche, leading to fewer general reviews.
- Potential for high implementation costs or steep learning curves for new users of advanced AI diagnostic tools.
- Lack of extensive discussion or user feedback on platforms like Reddit, suggesting a smaller public footprint outside of industry news.
Based on reviews from: PRNewswire (for FDA clearance news), Healthcare IT News/Reviewers (general industry analysis), Google Search (for general news and articles), G2 (searched, limited results), Glassdoor (searched, limited results), Capterra (searched, limited results), Reddit (searched, limited results)
Last updated: 2026-07-18
Videos
News, demos, and interviews about Neurophet.
Videos load interactively. If none appear, search YouTube for Neurophet →
Frequently Asked Questions
Related Companies
Intelligent Voice AI (IVAI) is an agentic AI platform that deploys AI voice agents specifically designed for healthcare, insurance, legal, and home services businesses. For physicians and medical practices, IVAI’s Evolve AI Agents act as an AI workforce, not just an answering service, handling a comprehensive range of administrative and operational tasks. These agents can […]
Dext, formerly known as Receipt Bank, is a company that specializes in bookkeeping automation, leveraging data, technology, and applied AI to enhance productivity and efficiency for businesses, accountants, and bookkeepers. [3, 16] Their platform is designed to streamline financial document management and automate bookkeeping tasks, aiming to simplify the accounting process and enable more informed […]
Cortex (https://www.cortex.app) is an AI-powered internal developer portal designed to enhance engineering excellence and streamline software development workflows. For physicians, this translates to a platform that can indirectly improve healthcare technology by enabling engineering teams to build more reliable, secure, and efficient software. The platform helps in cataloging, scoring, and assigning actions to improve service […]
Nino is an AI-powered financial planning and tax service that aims to provide comprehensive financial guidance. For physicians, Nino’s AI software can help manage income, student loans, and plan career transitions, such as moving from training to practice or considering practice ownership. The platform allows physicians to view loans, income, and savings in one place, […]
Coral AI is a healthcare artificial intelligence company that aims to streamline administrative workflows for healthcare providers, ultimately accelerating patient access to care. The company’s AI-driven platform integrates with existing healthcare systems, including EHRs, fax lines, and payer portals, to automate complex administrative tasks. This includes patient intake, prior authorizations, billing, compliance, and patient outreach. […]
SamaCare is a healthcare AI company that provides a cloud-based workflow intelligence platform designed to streamline the prior authorization process for specialty medications. The company’s platform aims to reduce the administrative burden on medical practices, improve approval rates, and add predictability to patient care. By digitizing the often manual and paper-heavy prior authorization process, SamaCare […]